Comparison of the occurrence of mold infection among patients receiving chemotherapy for acute leukemia versus patients undergoing stem cell transplantation

European Journal of Haematology

Volumn 87, Issue 5, 2011, Pages 419-425

  Janssen, Anke ^a   van der Bruggen, Tjomme ^a   Haas, Pieter Jan A ^a   de Jong, Pim A ^a   Minnema, Monique C ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Acute leukemia; Aspergillosis; Graft versus host disease; Neutropenia; Stem cell transplantation

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; IDARUBICIN; MELPHALAN; MITOXANTRONE; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTEMIC MYCOSIS; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; MYCOSES; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; YOUNG ADULT;

EID: 80054024274     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2011.01678.x     Document Type: Article

References (25)

1. Chamilos G, Luna M, Lewis RE, Bodey GP, Chemaly R, Tarrand JJ, Safdar A, Raad II, Kontoyiannis DP. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006;91:986-9.
2. Cornet M, Fleury L, Maslo C, Bernard JF, Brucker G. Invasive Aspergillosis Surveillance Network of the Assistance Publique-Hopitaux de Paris. Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the greater Paris area. J Hosp Infect 2002;51:288-96.
3. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996;23:608-15.
4. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006;91:1068-75.
5. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002;100:4358-66.
6. Orasch C, Weisser M, Mertz D, Conen A, Heim D, Christen S, Gratwohl A, Battegay M, Widmer A, Fluckiger U. Comparison of infectious complications during induction/consolidation chemotherapy versus allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2009;45:521-6.
7. Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984;100:345-51.
8. Martino R, Subira M, Rovira M, Solano C, Vazquez L, Sanz GF, Urbano-Ispizua A, Brunet S, De la Camara R. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002;116:475-82.
9. Fukuda T, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG, Martin PJ, Storb RF, Marr KA. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003;102:827-33.
10. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the transplant-associated infection surveillance network (TRANSNET) database. Clin Infect Dis 2010;50:1091-100.
11. Muhlemann K, Wenger C, Zenhausern R, Tauber MG. Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies. Leukemia 2005;19:545-50.
12. Arnow PM, Sadigh M, Costas C, Weil D, Chudy R. Endemic and epidemic aspergillosis associated with in-hospital replication of aspergillus organisms. J Infect Dis 1991;164:998-1002.
13. Partridge-Hinckley K, Liddell GM, Almyroudis NG, Segal BH. Infection control measures to prevent invasive mould diseases in hematopoietic stem cell transplant recipients. Mycopathologia 2009;168:329-37.
14. Lentino JR, Rosenkranz MA, Michaels JA, Kurup VP, Rose HD, Rytel MW. Nosocomial aspergillosis: a retrospective review of airborne disease secondary to road construction and contaminated air conditioners. Am J Epidemiol 1982;116:430-7.
15. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, Lerner KG, Thomas ED. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974;18:295-304.
16. Filipovich AH, Weisdorf D, Pavletic S, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945-56.
17. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the european organization for research and treatment of Cancer/Invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC/MSG) consensus group. Clin Infect Dis 2008;46:1813-21.
18. Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001;32:1319-24.
19. Malagola M, Peli A, Damiani D, et al. Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases. Eur J Haematol 2008;81:354-63.
20. Auberger J, Lass-Florl C, Ulmer H, Nogler-Semenitz E, Clausen J, Gunsilius E, Einsele H, Gastl G, Nachbaur D. Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int J Hematol 2008;88:508-15.
21. Hahn-Ast C, Glasmacher A, Muckter S, Schmitz A, Kraemer A, Marklein G, Brossart P, von Lilienfeld-Toal M. Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006. J Antimicrob Chemother 2010;65:761-8.
22. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7-14.
23. Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010;116:5111-8.
24. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-59.
25. Perkhofer S, Lass-Florl C, Hell M, et al. The nationwide austrian aspergillus registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients. Int J Antimicrob Agents 2010;36:531-6.